Vicarious Surgical Inc.

Vicarious Surgical Inc. is a U.S.-based medical technology company developing a single-port robotic surgical system for minimally invasive procedures. Its platform combines miniaturized robotics, sensing, computer science, and 3D visualization to support surgeons performing operations through a small access point.

2.97

2.97

— Vicarious Surgical Inc.
%
Robotic surgical systems100% Single-port robotic platforms designed to support minimally invasive surgery.

The company’s intended customers are hospitals and ambulatory surgery centers that would purchase robotic systems for...

  • Hospitalsprimary

    Large acute-care hospitals that would buy the system for minimally invasive surgical procedures and operating-room capability.

  • Ambulatory surgery centersprimary

    Outpatient surgical facilities that would use the platform for selected procedures where efficiency and access matter.

  • Surgeons and clinical userssecondary

    Physicians and surgical teams who influence adoption based on usability, precision, and workflow benefits.

  • International healthcare providersemerging

    Non-U.S. hospitals and surgical centers that may adopt the system after regulatory approvals and market entry.

Vicarious Surgical is headquartered and manufactures in Waltham, Massachusetts, in the United States...

  • Headquartered in Waltham, Massachusetts
  • Manufacturing capabilities located at the U.S. headquarters
  • Primary regulatory and development focus in the United States
  • Future sales expected to expand internationally
  • International clinical trials and product studies may add complexity

The company is focused on advancing its single-port robotic surgery platform toward regulatory authorization and...

01
Obtain regulatory authorizationshort-term

Commercial sales depend on FDA and other regulatory approvals.

02
Prove clinical and economic valuemedium-term

Hospitals and surgeons need evidence of precision, efficiency, and outcomes before adoption.

03
Expand procedure coveragemedium-term

A broader indication set increases the addressable market and long-term adoption potential.

04
Prepare for commercial scale-upmedium-term

Manufacturing, supply chain, and sales infrastructure must support future system deployment.

The business depends on successful product development, regulatory approval, and eventual market acceptance of a...

critical

Regulatory approval risk

The company cannot generate product revenue until the system receives FDA authorization and other approvals.

Scope
Commercial launch timing
Materiality
high
critical

Going-concern and capital access risk

The company disclosed substantial doubt about its ability to continue as a going concern, reflecting dependence on external funding.

Scope
Liquidity and operating runway
Materiality
high
high

Product performance and liability risk

A surgical robot must work reliably in complex procedures, and defects could cause patient harm, recalls, or reputational damage.

Scope
System design, manufacturing, and clinical use
Materiality
high
high

Competitive risk

Established players such as Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, and CMR Surgical compete in robotic surgery.

Scope
Market adoption and pricing power
Materiality
high
high

NYSE listing compliance risk

The company received notice that it was no longer in compliance with minimum market capitalization standards.

Scope
Public market access and investor perception
Materiality
high
medium

Supplier concentration risk

Some components are sole-sourced or single-sourced, which can disrupt assembly and testing if supply is interrupted.

Scope
Manufacturing and preclinical/clinical builds
Materiality
medium
Warrant liabilities
Can create non-cash gains or losses in the statement of operations
Pre-revenue expense recognition
Makes period-to-period comparisons sensitive to spending cadence
Fair value of investments
Can influence other income and cash management disclosures
Going-concern assessment
Important for interpreting liquidity and financial statement assumptions

: 29.4.2026